USE OF ANNELID HEMOGLOBIN AS A BACTERICIDE, PARTICULARLY TO PREVENT AND / OR TREAT PERIODONTAL DISEASE

MX433731BActive Publication Date: 2026-05-19HEMARINA
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
MX · MX
Patent Type
Patents
Current Assignee / Owner
HEMARINA
Filing Date
2020-07-15
Publication Date
2026-05-19

AI Technical Summary

Technical Problem

Current treatments for periodontal diseases, particularly periodontitis, are inadequate in effectively preventing and treating bacterial infections caused by gram-negative anaerobic bacteria, leading to tissue destruction and complications such as periodontal pockets and bone resorption.

Method used

Utilizing extracellular hemoglobin from annelids, specifically Arenicola marina, which exhibits anti-biofilm activity and bactericidal effects against gram-negative pathogens like P. gingivalis and T. denticola, by supplying oxygen and inhibiting bacterial growth in planktonic and biofilm cultures.

Benefits of technology

The extracellular hemoglobin from annelids effectively reduces bacterial viability and biofilm formation, preventing tissue damage and promoting healing in periodontal tissues, while also offering potential benefits like halitosis prevention and tooth whitening.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention relates to the use of a molecule selected from among the oxygen transporters of marine invertebrate animals, preferably from among a globin, a globin protomer or an extracellular hemoglobin of annelids, as a bactericide, in particular for preventing and / or treating periodontal disease.
Need to check novelty before this filing date? Find Prior Art